Partnering opportunity

Optimization of therapeutic oligonucleotide efficacy for the treatment of solid tumours by innovative nanoparticles

Summary

A Dutch clinical stage company is developing a new generation of nanomedicines. Their aim is to use their nanoparticle technology to improve the efficacy and safety profiles of current and novel drugs for the treatment of solid tumours. As part of their development strategy, they are looking for a license and/or technical cooperation agreement with academic research labs to exploit their nanoparticles for enhanced tumour targeting of new oligonucleotides with therapeutic potential.

Technical Specification or Expertise Sought

Biomedicine/biotechnology academic research labs with proprietary oligonucleotides with therapeutic potential for the treatment of solid tumours. Potential collaborators and their oligonucleotide should fit the following criteria: • Proof of concept at least in vitro but preferably in vivo in a cancer model • Patent protected (filed after 2013), or be patentable • Oligonucleotide project must be active The Dutch company envisions a partnership in which the academic partner performs the in vitro and in vivo evaluations of the applicable oligonucleotides upon entrapment in optimized nanoparticles with the company’s input.

Partner sought

The Dutch company is looking for a license agreement and/or a technical cooperation agreement with preferably an academic research lab that is open to licensing or partnering. The SME envisions a partnership in which the academic partner performs the in vitro and in vivo evaluations of the applicable oligonucleotides upon entrapment in optimized nanoparticles with the company’s input.

Description

A Dutch clinical stage company developing a new generation of nanomedicines, aims to use their proprietary nanoparticle technology to improve the efficacy and safety profiles of current and novel drugs for the treatment of solid tumours. In humans, their platform improves the pharmacokinetics and reduces life-threatening toxicities for drugs already used in the clinic. Moreover early signs of efficacy in humans have also been observed. As part of the company’s development plan, they are looking for collaborative opportunities to exploit their nanoparticles for enhanced tumour targeting of new oligonucleotides with therapeutic potential. Oligonucleotides, RNA (ribonucleic acid) or DNA (deoxyribonucleic acid), are of great therapeutic potential, as they may allow to act on to date undruggable targets, as well as utilising novel and unexplored mechanisms of action. Despite this, selective tissue targeting of oligonucleotides has been a main challenge, as when administered naked they are unstable and may trigger undesired immunogenic responses. Effective targeting towards the appropriate intracellular compartment has also been a major hurdle thus far. These constraints have hampered the development of oligonucleotides in the clinic. The company’s proprietary nanoparticle platform allows the entrapment of therapeutic molecules, to improve their pharmacokinetics upon intravenous (IV) or subcutaneous (SC) administration and to target them to cancer tissue where these molecules can be released extracellularly or intracellularly. The platform also offers the promise to target oligonucleotides to the applicable intracellular compartment. The client have generated initial in vivo proof of concept of enhanced oligonucleotide tumour targeting, cellular uptake, and knockdown of the target gene of interest. To move forward the Dutch SME is looking for proprietary oligonucleotides having therapeutic potential that they can in-license and develop to the market in combination with their platform. The therapeutic candidate needs to fit the following criteria: • Oligonucleotides having therapeutic potential for the treatment of solid tumours, e.g.:  Gene expression modulating properties: siRNA (small interfering RNA), Antisense, shRNA (short hairpin RNA), miRNA (micro RNA), TFO (triplex forming oligonucleotides), or  Immune stimulatory properties: CpG (C = cytosine triphosphate deoxynucleotide, p = phosphodiester link, G = guanine triphosphate deoxynucleotide), poly I:C (polyinosinic:polycytidylic acid) like oligonucleotides  Other applicable mechanisms The company is looking for a license and/or technical cooperation agreement with academic research labs to exploit their nanoparticles.

Advantages and innovations

Not available

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted,Patents granted,Granted patent or patent application essential


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company